Tillkännagivande • Apr 17
Proteome Sciences plc Announces Directorate Change with the Departure of Non-Executive Director Roger Mcdowell Proteome Sciences plc announced that Roger McDowell, after 11 years on the Board as a non-executive director, believes it is the right time for him to step down and to not seek re-election at the upcoming Annual General Meeting. Roger McDowell departs from the Board as a non-executive director. Reported Earnings • Apr 16
Full year 2025 earnings released: UK£0.01 loss per share (vs UK£0.012 loss in FY 2024) Full year 2025 results: UK£0.01 loss per share (improved from UK£0.012 loss in FY 2024). Revenue: UK£3.76m (down 23% from FY 2024). Net loss: UK£3.06m (loss narrowed 10% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Tillkännagivande • Apr 15
Proteome Sciences plc, Annual General Meeting, May 14, 2026 Proteome Sciences plc, Annual General Meeting, May 14, 2026. Location: sp angel corporate finance llp, prince frederick house, 35 39 maddox street, w1s 2pp, london United Kingdom New Risk • Apr 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£5.54m market cap, or US$7.46m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (19% increase in shares outstanding). New Risk • Jan 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£6.86m market cap, or US$9.46m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding). Tillkännagivande • Jan 29
Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million. Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 7,542,856
Price\Range: £0.0175
Transaction Features: Regulation S Tillkännagivande • Jan 26
Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million. Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,428,572
Price\Range: £0.0175
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 18,571,428
Price\Range: £0.0175
Transaction Features: Subsequent Direct Listing Reported Earnings • Sep 28
First half 2025 earnings released: UK£0.007 loss per share (vs UK£0.007 loss in 1H 2024) First half 2025 results: UK£0.007 loss per share (in line with 1H 2024). Revenue: UK£1.86m (down 16% from 1H 2024). Net loss: UK£2.14m (loss narrowed 3.3% from 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. New Risk • Sep 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£5.18m (US$6.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.5m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£5.18m market cap, or US$6.91m). New Risk • May 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.0m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-UK£6.5m). Earnings have declined by 64% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£10.5m market cap, or US$14.1m). Reported Earnings • Apr 11
Full year 2024 earnings released: UK£0.011 loss per share (vs UK£0.008 loss in FY 2023) Full year 2024 results: UK£0.011 loss per share (further deteriorated from UK£0.008 loss in FY 2023). Revenue: UK£4.89m (down 2.8% from FY 2023). Net loss: UK£3.41m (loss widened 39% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance. Tillkännagivande • Apr 10
Proteome Sciences plc, Annual General Meeting, May 16, 2025 Proteome Sciences plc, Annual General Meeting, May 16, 2025. Location: allenby capital, 5 st helens place, ec3a 6ab, london United Kingdom Tillkännagivande • Apr 04
Proteome Sciences plc to Report Fiscal Year 2024 Results on Apr 10, 2025 Proteome Sciences plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 10, 2025 New Risk • Apr 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (UK£12.0m market cap, or US$15.5m). New Risk • Jan 02
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: UK£4.0m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (UK£4.0m revenue, or US$5.0m). Market cap is less than US$100m (UK£10.0m market cap, or US$12.4m). New Risk • Nov 01
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.38m (US$9.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (UK£7.38m market cap, or US$9.53m). New Risk • Sep 20
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.38m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (UK£7.38m market cap, or US$9.83m). New Risk • Sep 14
New major risk - Revenue and earnings growth Earnings have declined by 49% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£8.41m market cap, or US$11.0m). Tillkännagivande • Sep 13
Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025 Proteome Sciences plc announced that Dr Mariola Soehngen has notified the Company of her intention to step down as Chief Executive Officer of the Company after four years of service at the end of January 2025. The process to appoint a successor has been initiated. New Risk • Apr 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-UK£3.1m). Minor Risk Market cap is less than US$100m (UK£9.06m market cap, or US$11.3m). Reported Earnings • Apr 10
Full year 2023 earnings released: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022) Full year 2023 results: UK£0.008 loss per share (down from UK£0.004 profit in FY 2022). Revenue: UK£5.03m (down 35% from FY 2022). Net loss: UK£2.44m (down 284% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Tillkännagivande • Apr 10
Proteome Sciences plc, Annual General Meeting, May 16, 2024 Proteome Sciences plc, Annual General Meeting, May 16, 2024, at 11:00 Coordinated Universal Time. Location: Allenby Capital, 5 St Helen's Place, London United Kingdom New Risk • Mar 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Negative equity (-UK£1.4m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£12.2m market cap, or US$15.6m). New Risk • Feb 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-UK£1.4m). Minor Risk Market cap is less than US$100m (UK£13.3m market cap, or US$16.7m). Tillkännagivande • Oct 05
Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling Reagents Proteome Sciences plc announced the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents. Where more traditional approaches can measure a few 10s of proteins on each cell using antibody labelling, SysQuant® SCP can identify more than 1,000 proteins in each study of 576 single cells and provides novel insights into individual cell biology and heterogeneity. Proteome Sciences is one of the first commercial providers of such studies whichare expected to significantly improve the performance of drug development across multiple diseases including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders. Whilst in its infancy, the field of single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes. At the same time, the complexity of the process along with the need to purchase and maintain costly equipment represents a significant barrier to entry. The SysQuant® SCP pipeline generates and analyses quantitative mass spectrometry data to reveal subtle changes not only in individual cells but also within sub-populations of that same main cell type. This data will greatly improve understanding of the biological drivers of heterogeneity and evolution in the contexts of disease and response to therapy, which will offer new therapeutic and diagnostic targets for personalized medicine. Reported Earnings • Aug 26
First half 2023 earnings released: UK£0.002 loss per share (vs UK£0 in 1H 2022) First half 2023 results: UK£0.002 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£3.21m (down 1.0% from 1H 2022). Net loss: UK£578.0k (down UK£641.0k from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Aug 26
Now 43% undervalued Over the last 90 days, the stock is up 7.8%. The fair value is estimated to be UK£0.095, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 64%. Reported Earnings • Apr 08
Full year 2022 earnings released: EPS: UK£0.004 (vs UK£0 in FY 2021) Full year 2022 results: EPS: UK£0.004 (up from UK£0 in FY 2021). Revenue: UK£7.78m (up 52% from FY 2021). Net income: UK£1.33m (up UK£1.25m from FY 2021). Profit margin: 17% (up from 1.4% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 05
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up UK£425.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 01
Full year 2021 earnings released: EPS: UK£0 (vs UK£0.001 in FY 2020) Full year 2021 results: EPS: UK£0 (down from UK£0.001 in FY 2020). Revenue: UK£5.13m (up 7.9% from FY 2020). Net income: UK£72.0k (down 76% from FY 2020). Profit margin: 1.4% (down from 6.2% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Mar 29
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 31%. The fair value is estimated to be UK£0.048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years. Buying Opportunity • Mar 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 29%. The fair value is estimated to be UK£0.047, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years. Buying Opportunity • Feb 22
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 27%. The fair value is estimated to be UK£0.054, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years. Reported Earnings • Aug 03
First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£1.97m (up 3.7% from 1H 2020). Net loss: UK£425.0k (loss narrowed 17% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 131% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 03
Full year 2020 earnings released: EPS UK£0.001 (vs UK£0.001 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£4.75m (up 2.1% from FY 2019). Net income: UK£295.0k (up 98% from FY 2019). Profit margin: 6.2% (up from 3.2% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. 